BAYRY Bayer AG

Mentions (14)

• Newswsj.com·3d ago·Negative

  Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.

  View source ↗
• Newsbusinesswire.com·3d ago·Positive

  Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer's long-term growth strategy and commitment to innovation and patient access in its l

  View source ↗
• Newsreuters.com·6d ago·Negative

  Bayer faces trial test of remaining Roundup claims after US Supreme Court win Attorneys for ​three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately ‌test its Roundup weedkiller before selling it, starting a trial that could help determine the viability of some Roundup lawsuits after a US Supreme Court ruling in Bayer's favor this year.

  View source ↗
• Newszacks.com·19d ago·Neutral

  FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

  View source ↗
• Newsbusinesswire.com·19d ago·Negative

  Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adult

  View source ↗
• Newsreuters.com·21d ago·Negative

  Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its ​weedkiller Roundup causes cancer, saying there is no other way to resolve the litigation that has weighed on the German ‌company for years.

  View source ↗
• Newsreuters.com·25d ago·Negative

  Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court Bayer's Monsanto unit heads to a Missouri state court on Monday seeking ​approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkiller Roundup ‌causes cancer.

  View source ↗
• Newsbusinesswire.com·25d ago·Negative

  Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026

  View source ↗
• Newszacks.com·25d ago·Neutral

  Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.

  View source ↗
• Newsbusinesswire.com·26d ago·Neutral

  U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.

  View source ↗
• Newsseekingalpha.com·33d ago·Neutral

  Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript Bayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division Transcript

  View source ↗
• Newsmarketbeat.com·33d ago·Negative

  Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s clean EBITDA margin and more than €3 billion in free operating cash flow by 2029.

  View source ↗
• Newsreuters.com·34d ago·Neutral

  Bayer says Crop Science unit makes progress on product launches Bayer said on Wednesday its Crop Science business had introduced ​two out of 10 planned new ‌products with peak annual sales of at least €500 million ($579 million) each and mapped ​out further market launches.

  View source ↗
• Newszacks.com·52d ago·Positive

  3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

  View source ↗